

TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: +91 79 26599000 Fax: + 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

Statement of Standalone A	udited Results fo	or the Quarter a	nd Half Voor End	ed 30-Sep 3017	n Crores except	per share dat
		Quarter ended		Half Year ended		
Particulars	30-Sep-2017	30-Jun-2017	30-Sep-2016	30-Sep-2017	30-Sep-2016	Year ended
Revenue		(1)		30 3cp 2017	30-3ep-2010	21-iAIGI-501
Net Sales (including excise duty)	1002	024	1027	4000		
Other operating income	24	834	1037	1836	2325	446
Revenue from operations (net)	1026	13 847	21	37	57	13
Other income	91	109	1058	1873	2382	459
Total Revenue	1117	956	59 1117	200	108	29
Expenses		330	1117	2073	2490	489
Cost of materials consumed	177	220	207			
Purchases of stock-in-trade	41	239	297	416	639	117
Changes in inventories of finished goods, work-in-	41	70	54	111	104	22
progress and stock-in-trade	62	(88)	(34)	(26)	(5.4)	
Employee benefits expense	207	187	185	(26) 394	(54)	(1:
Finance costs	51	55	51	106	364 99	69
Depreciation and amortisation expense	78	74	64	152		20
Other expenses	303	318	312	621	125 618	26: 138:
Total expenses	919	855	929	1774	1895	393
Profit before tax	198	101	188	299	595	95
Fax expense			1 8 = 1 =	233	333	93
Current Tax	42	22	40	64	127	22
Deferred Tax	(2)	(5)	(21)	(7)		22
otal tax expense	40	17	19	57	(38) 89	(121 10
let profit for the period	158	84	169	242	506	85
ther comprehensive income				THE THE PARTY OF	300	83
Items that will not be reclassified to profit or loss	(3)	(2)	(2)	(6)	400	
Income tax relating to items that will not be reclassified	(3)	(3)	(3)	(6)	(6)	(1
to profit or loss	1					
Items that will be reclassified to profit or loss	(75)	1	1	2	2	
Income tax relating to items that will be reclassified to	(75)	(67)	65	(142)	60	15
profit or loss	26	23	(23)	49	(21)	tr.
otal other comprehensive income	(51)	(46)	40	(97)	(21)	(5.
otal comprehensive income	107	38	209	145		90
aid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62	541	950
aid up Debt Capital		04.02	04.02	1490	84.62	84.6
ther Equity excluding Revaluation Reserves					490	1490
etworth				4433 4518	4163	4369
ebenture Redemption Reserve		4 - 3 - 3		373	123	4454 373
rnings per share (of Rs. 5/- each) (not annualised for					123	373
e quarter):						
Basic	9.31	4.97	9.96	14.28	29.87	50.48
Diluted	9.31	4.97	9.96	14.28	29.87	50.48
ebt Equity Ratio				0.53		
ebt Service Coverage Ratio	- H & A W-				0.59	0.55
terest Service Coverage Ratio				2.61 3.88	4.19 7.10	1.39 5.78



Ratios have been computed as follows:-

a) Debt to Equity: Debt / Net Worth

Debt: Long term borrowings (Current & Non Current Portion)

Net worth: Share Capital + Reserves & Surplus

b) Debt Service Coverage Ratio: EBIT / (Interest on term & working capital debt + Principal repayments of Long term debt)

(EBIT : Profit before Taxes +/(-) Exceptional Items + Interest Expense)

c) Interest Service Coverage Ratio: EBIT / Interest Expense

Notes:

- 1 The above results were reviewed by the Audit and Risk Management Committee and approved by the Board of Directors in their respective meetings held on 03-Nov-2017. The auditor have carried out audit of the above said results. There is no qualification in the Auditors report on this statement of financial results.
- 2 The Company operates in a single segment i.e Generic Formulation Business.
- 3 Standalone Statement of Assets and Liabilities

	Audited			
Particulars	As at	As at		
	30-Sep-2017	31-Mar-2017		
ASSETS				
Non-current assets				
Property, plant and equipment	1887	1833		
Capital work-in-progress	509	462		
Goodwill	144	144		
Other intangible assets	1658	1547		
Intangible assets under development	16	11		
Financial assets				
Non-current investments	149	148		
Long-term loans	70	109		
Other Financial Assets	21	95		
	240	352		
Non-current tax assets (net)	55	42		
Other non-current assets	97	116		
Sub-total - Non-current assets	4606	4507		
Current assets				
Inventories	1054	1032		
Financial assets				
Current investments	998	787		
Trade receivables	957	1018		
Cash and cash equivalents	98	78		
Bank deposits other than cash and cash	50	/6		
equivalents*	0	0		
Short-term loans	70			
Other Financial Assets	175	43		
	2298	296 2222		
Other current assets	356	290		
Non-current assets classified as held for sale*				
Sub-total - Current assets	3708	0 3544		
TOTAL - ASSETS	8314	8051		



[Rs. in Crores] Audited **Particulars** As at As at 30-Sep-2017 31-Mar-2017 **EQUITY AND LIABILITIES** Equity Share capital 85 85 Other Equity 4433 4369 4518 4454 Non-current liabilities **Financial Liabilities** Long-term borrowings 2083 2209 Other financial liabilities 2092 2216 Long-term provisions 125 126 Deferred tax liabilities (net) 43 101 Other non-current liabilities* 0 Sub-total - Non-current liabilities 2260 2443 **Current liabilities** Financial Liabilities Short-term borrowings 250 Trade payables 574 548 Other financial liabilities 546 495 1370 1043 Short-term provisions 57 55 Other current liabilities 109 56 Sub-total - Current liabilities 1536 1154

TOTAL - EQUITY AND LIABILITIES

* Less than Rs. 1 crore

4 (a) The listed Non Convertible Debentures of the company aggregating to Rs. 1490 crores as on 30-Sep-2017 (previous year ended Rs 490 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.

8051

8314

- (b) The listed Non Convertible Debentures of the company aggregating to Rs. Nil as on 30-Sep-2017 (previous year ended Rs 1000 crores) to be secured by way of first pari passu charge on certain specified immovable & movable assets and identified trademarks of the Company.
- Results for the year ended 31-Mar-2017 and quarter and half year ended 30-Sep-2016 include exceptional revenues and profits primarily on account of launch of a new product in the USA which had limited competition.
- 6 The figures for the corrosponding previous period have been restated/regrouped wherever necessary, to make them comparable.

FOR TORRENT PHARMACEUTISALS LIMITED

SAMIR MEHTA
Executive Chairman

Place : Mumbai, Maharashtra

Date: 03-Nov-2017

